The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Immuno-oncology paving the way in MDS
Uma Borate, MD, Oregon Health & Science University, Portland, OR, outlines novel treatments against myelodysplastic syndromes (MDS). Specifically discussed is the use of antibody-based therapies such as MBG453, small molecule inhibitors such as venetoclax, and therapies including APR246 that targets mutant p53. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
